Seemingly bad news can sometimes be really good news. I think a recent study for Eli Lilly's (LLY -0.28%) rival to Novo Nordisk's massively successful Ozempic and Wegovy provides a great case in point.
Results from the Surmount-4 clinical trial were published on the Journal of the American Medical Association's website on Dec. 11, 2023. Researchers found that patients who…